Back to Search Start Over

[Translated article] Drug Survival in Cyclosporine Treatment for Moderate to Severe Atopic Dermatitis: Analysis of the Spanish Atopic Dermatitis Registry (BIOBADATOP)

Authors :
Couselo-Rodríguez, C.
Batalla, A.
Carrascosa, J.M.
Chicharro, P.
González-Quesada, A.
de la Cueva, P.
Giménez-Arnau, A.M.
Gilaberte, Y.
Rodríguez-Serna, M.
Montero-Vilchez, T.
Ruiz-Villaverde, R.
Elosua-González, M.
Silvestre-Salvador, J.F.
Munera-Campos, M.
Sánchez-Pérez, J.
Carretero, G.
Mauleón-Fernández, C.
Curto-Barredo, L.
Ballano-Ruiz, A.
Botella-Estrada, R.
Arias-Santiago, S.
Navarro-Triviño, F.J.
Roustan-Gullón, G.
Betlloch, I.
del Alcázar, E.
Abalde-Pintos, M.T.
Suárez-Perez, J.
García-Doval, I.
Descalzo, M.Á.
Flórez, Á.
Source :
Actas Dermo-Sifiliográficas; 20240101, Issue: Preprints
Publication Year :
2024

Abstract

The past 5 years have seen a proliferation of new treatments for atopic dermatitis (AD). We analyzed recent drug survival data for cyclosporine in this setting. Because the Spanish National Healthcare system requires patients with AD to be treated with cyclosporine before they can be prescribed other systemic treatments, drug survival for cyclosporine may be shorter than in other diseases.

Details

Language :
English
ISSN :
00017310 and 21735778
Issue :
Preprints
Database :
Supplemental Index
Journal :
Actas Dermo-Sifiliográficas
Publication Type :
Periodical
Accession number :
ejs65437701
Full Text :
https://doi.org/10.1016/j.ad.2023.07.028